A federal jury in Massachusetts on Friday sided with Amphastar Pharmaceuticals in a patent battle with Momenta Pharmaceuticals and Sandoz, finding that Momenta’s patent for a generic blood thinner was invalid and that the company couldn’t enforce it anyway.